Coherus Oncology, Inc Investor Event Transcript, Nov 10, 2026
Coherus Oncology, Inc. (CHRS)
Coherus Oncology is prioritizing esophageal cancer after eight out of nine evaluable first-line esophageal squamous cell patients responded, an 89% ORR. The company is cutting headcount by 30%, primarily on the non-commercial side. It plans to meet FDA early in 2027 on the recommended phase two dose. AI summary
Conference Transcript - CHRS 2026-11-10
Paul Jang, Analyst — Guggenheim
All right, so welcome to the first session of the second day of the Guggenheim Conference. My name is Paul Jang. I'm a biotech analyst with Guggenheim, and I'm very pleased to welcome our first company of the day to kick things off, Coheris Oncology. And with us today is Danny Lanphier, President and CEO, Rash Diaz, CMO, Teresa Lavallee, Chief Scientific and Development Officer. Thank you all for joining. Thank you, Paul. It's good to be with you today. We appreciate the bank inviting us to the conference. Great. So maybe just to kick things off for those who might be newer to the story, could you provide a quick introduction to the company and the current pipeline in the commercial product?
Denny Lanphier, CEO
Sure. So a couple of years ago, we acquired Service Oncology and then set about divesting our biosimilar business, which went pretty well. We did about $800 million in divestitures and paid off almost $500 million in debt. We dropped $250 million onto the balance sheet and set about the task of developing tagmal ketog, or CCR8, dereg depleter, and also casdozo ketog, or anti-out 27. We had a very broad clinical plan for tagmal ketog, which encompassed a number of tumors, esophageal first line, second line head and neck, various gastric tumors, and even fourth line CRC. What we're very happy with now is having cast our net so broadly, we're able now to focus on esophageal, and so this is something I think Dr. Diaz will talk about the data, but it allows us really to strategically focus the organization in a way that we haven't been able to do before. So we've taken one particular disease focus, first line and second line During the esophageal, now we're going to pursue various accelerated approaches, particularly in second line with the priority. But the strategic prioritization has a number of other benefits for us. First of all, it's very expensive, and there's a lot of overhead in pursuing so many clinical indications concurrently. And so by focusing, we're able really to put ourselves in a position where we can reduce the organization. At the same time, a couple other very fortuitous things happened. We had, from the divestiture, we had... Transition Services Agreements with the Acquirer Intesa Court. And so those are all now winding down. And that actually inflated our burn a bit. I think it was a little confusing for investors, but now we're in a position where we don't have to deal with that. And then the third fortuitous thing which occurred is that we have now completed our process transfer of toropalumab, our PD-1, from China to the U.S. So that overhead and that burn also is being dramatically reduced. So all three of these things allowed us really to right-size the organization here. We are putting in place a 30% headcount reduction that's primarily across the non-commercial side of the business And focusing very, very tightly on esophageal and where we can go. And just, I'll let Raj talk about the data as indicated, but what I like about esophageal is that it's a very large market ex-US. It's the sixth leading cause of cancer deaths. And there's over 400,000 patients annually ex-US, particularly in Asia. So one of our strategies we've talked about for some time is the partnering, and being able to bring in partnering funds, offset clinical costs, expenses, And then have partners, of course, contribute to future clinical development costs. So now that we have an indication and we have very strong data, now we're able to go and look for partners for TAGMO and Ketug, and we actually have a financial advisor that we're signing up to go and help us with that. So that's all worked really, really well. The other thing that I would note about the reductions in the organization and the savings What happens is they amount to about six or seven million dollars a quarter, and that has duration to it. So what we're going to do... Really is now we're able to drive the company to core burn break even a little earlier. So one of the things we're focusing on is driving the sales of Lactorsi up from like 14 or 15 million up to like 25, 30 or 35 million, at which point the core burn, which is basically the overhead and the cost and so forth without the clinical trials. So that'll be taken care of. But I think that's very exciting because that way it puts us in a self-sufficiency mode where we're going. But just back to the data for a moment, I think it's very exciting data. The mechanism of action for TREG depletion now is coming very clear. Dr. LaVallee can talk a little bit about that. But I think we're very pleased with the way things are working out for us.
Paul Jang, Analyst — Guggenheim
Great. So, yeah, lots to chew on there, but it's great to talk to you guys after you provided such a meaningful clinical update as well as strategic update. So, maybe starting with the clinical part of things, you know, we recently saw the data for TAGMO across a basket of solid tumor indications, and you've announced you're prioritizing esophageal. So, can you sort of walk us through what you saw in that update and why the decision to prioritize esophageal?
Rash Diaz, Other
Yeah, good morning, Paul. No, thank you. So, you know, let me just take a step back, first of all. We ran a very intentional program where we looked at five different tumor settings associated with mucosal immunity, where the prevalence of Tregs, CCR8-positive Tregs, was high. And really, our intention overall with this TregCheck program was to do two things. Number one, show activity and see where we had activity. And secondly, to really see where the activity was strongest, where we can then progress further in terms of development. Broadly speaking, we learned three things with the program. First of all, that we can reverse in the second-line setting in PD-1 experienced patients, that we could reverse PD-1 resistance. Secondly, we also learned that in the first-line setting, so earlier, that we could enhance antitumor activity in combination with chemotherapy, which is, of course, important, right? Because we know that the immune system is more active in the first line setting or in earlier lines. And thirdly, we also learned that in colder tumors, so PD-L1 low, PD-L1 negative, colorectal cancer, for example, that we could activate the immune system. So broadly, we learned from this program, we did see activity across all of the different tumor settings that we looked at, which was very positive. Our strongest signal, as you alluded to, was in esophageal cancer. So let me just briefly take you through the data. In first-line esophageal squamous cell, we saw eight out of nine of the evaluable patients responded, including one complete response, which is pretty encouraging. So that equated to an 89% ORR. Just for benchmarks purposes, the current standard of care is a PD-1 plus chemotherapy that is only in PD-L1 positive patients. And their ORR is roughly in the range of 44, depending on which trial and which agent you're looking at, somewhere between 44% and 60%. Ours was 89% overall. It was 100% for PD-L1 positive patients, so obviously very encouraging there, despite being a small patient number. So strong signal in first line. In second line, if we looked at both the esophageal squamous histology as well as the esophageal adenocarcinoma histology, and this is an area of huge unmet medical need. So as we looked at those two different, both of those histologies in the second line setting, we saw overall out of nine evaluable patients, we saw three partial responses. So a 33% If we added in the additional unconfirmed partial response as well, that then went up to 44%. And again, the benchmarks for this kind of setting is essentially chemotherapy, and that's around the 10% ORR range, typically between two to four months PFS, medium PFS. And again, whilst our data is not yet fully mature, we showed a medium PFS of the range of 5.5 months or thereabouts. Durability is important, so that's a very important metric, and if we also look at the, we've talked about the clinical benefit rate, right, which is CR plus PR plus six months of stable disease, the overall CBR rate was in the region of 55%, so also pretty encouraging. So that's an overall summary of the data and the focus in on esophageal specifically. So I think we're able to plant our flag now in esophageal overall, first line, second line, area of huge unmet medical need. Denny talked about the overall patient population, which globally is very large, and I think that's really where we're progressing initially within a focus in on second line, because I think, again, for three reasons. First of all, there's a huge unmet medical need. There's a potential fast path to approval, potentially leveraging some of the accelerated FDA designations, and, of course, the signal as well.
Denny Lanphier, CEO
The other thing that I would note, addition to Raj's remarks, is that Lacturzi has previously demonstrated strong activity in PD-1-negative patients in a background of chemotherapy in esophageal and actually is licensed in Europe accordingly. So this is very promising, and from the viewpoint of partnering, it puts us in a position where there's already a market, where Lacturzi is in this indication, and Europe. So this is fortuitous for us.
Paul Jang, Analyst — Guggenheim
Makes sense. So, can you talk about, I guess, the next steps in terms of, I guess, confirming the signal or further expanding it? Are you going to have additional follow-up? Are you going to have more patients? And what should the cadence of, I guess, subsequent updates be in the next year or so?
Denny Lanphier, CEO
Dr. Lavallee is busy working on the regulatory approach. Teresa, do you want to just review your thoughts?
Theresa LaVallee, Other
Yeah, so immediate next steps are twofold. First, it's very important to align with FDA on the dose. I mean, we've seen a lot of companies that have had to dose optimize later. We've done that early, so we are putting together a meeting request right now to go to FDA early in 2027 to get alignment on the recommended phase two dose. Importantly, we've incorporated Western patients, U.S. patients, in our study early. So we've gotten that data set to show applicability to U.S. medical practice and U.S. patients. I mean, the CR patient that Rush referred to actually is a U.S. patient, and we have responses in the second line setting in U.S. as well. The second meeting that we intend to have with FDA in the first part of next year is on a type B meeting on development and esophageal second line and talk to them about plans to go towards first line as we get more mature follow-up and more patients. It's more complicated on top of standard of care because of contribution of effect and showing PFS and OS in that setting, so we would align with them on a randomized study and the opportunity for expedited development, fast-track, breakthrough, accelerated approval.
Paul Jang, Analyst — Guggenheim
Okay, and so can you just expand on how you're currently thinking about the second-line registrational study? I mean, pending FDA feedback, of course, but this would conceivably be a chemo-free regimen. You know, how do you think about including both squamous and adenocarcinoma histologies, and you know, what are the sort of parameters in terms of the bar for perhaps accelerated approval?
Theresa LaVallee, Other
Yeah, so the idea of doing histologies, I think a lot of people are familiar with lung cancer, where we often talk about adeno and squamous, and some development is exclusive to one subtype or another. In the upper GI, You see a variety of trials of how people put together the different gastric, GEJ, esophageal, adenosquemus. The idea of focusing in on esophageal with both histologies is something that has precedence. Pembro did it both in the first line and second line setting, keynote 590 and keynote 181. So I don't, this is something that we look at treating the disease. And in terms of benchmarks, Rush very nicely described what chemotherapy does. So in a PD-1 refractory, PD-L1 low is not indicated in the first-line setting. And we have activity in PD-L1 negative patients. So chemotherapy would still be the comparator there. And it's 10%. So a threefold increase is already worthy of a conversation with FDA of what their expectations would be. And the PFS going from two and a half, three and a half months to five and a half months, early immature data set, but trending in the right direction. And having patients on study of protein eight months, which is the median overall survival, I think gives us a lot of data, the totality of the data, to really talk with FDA about a chemo-free regimen in this patient population.
Paul Jang, Analyst — Guggenheim
Okay. And I guess, how should we think about the size of the opportunity in the second line, which is the initial focus indication, when you think about the type of trial that you might run?
Theresa LaVallee, Other
Yeah, so, I mean, we talk with FDA about a randomized phase two. We have to align with them on the numbers, but this... And the team is working through scenarios for either a randomized phase two, you know, enough to see the signal, or doing a seamless design where you would then go into the overall survival with a larger part A and a part B, or two independent studies. And I think that will be the point of discussion with FDA. But, you know, you can imagine with the numbers we're sharing today, it would be a very manageable phase two pivotal for accelerated approval. But we can give more color on that after we align with FDA because what really matters is what they think.
Paul Jang, Analyst — Guggenheim
Sure, yeah. And then obviously the signal in frontline was also very compelling. I guess at this point, given the initial focus on second-line plus, what is your line of sight into moving frontline as well into a registrational study? That's a point.
Theresa LaVallee, Other
Yeah, I think that's a pretty tried and true path. I mean, the nice part about doing integrated development across the disease with a line to best in disease treatment. So, as Raj said, in the first line setting, very importantly, we've shown we can move earlier in disease where the immune system is more intact. We can go beyond chemo plus PD-1 and open up in the U.S. the PD-L1 negative patient population, so expand the patient population. So importantly, what I'm describing is what's the unmet medical need because that's always important for risk-benefit assessment. So contribution of effect and getting that is a bigger study, longer study with a pretty active regimen. So we We will have conversations with FDA about that and what that would look like and can update you afterwards, but we'd be keen to move that forward. Okay.
Rash Diaz, Other
Just one thing I'll add to Teresa's remarks, Paul. You know, we talked about the huge unmet medical need in esophageal generally. Second line, that is particularly marked because of some of the benchmarks we talked about. But starting second line first before first line allows us then to follow up these first-line patients for longer because, of course, they take a longer period of time to progress. So it allows that follow-up to happen initially in the first-line study whilst we start the second-line study as well. So I think there's a nice synergy there, too.
Paul Jang, Analyst — Guggenheim
So you're prioritizing esophageal, and as you've mentioned, you're sort of deprioritizing the other solitude and tumor indications, but I guess were there any key learnings from that experience in head and neck, colorectal, gastric cancer, and would we expect any additional follow-up from those patients as a way of learning more about TAGMO?
Rash Diaz, Other
Yeah, I can start, and Teresa can jump in, too. So I outlined some of the key things that we learned initially. So first of all, and these are very important in the sphere of immuno-oncology, first of all, that we can reverse PD-L1 or PD-1 resistance in the second-line setting. So PD-1 experienced patients, we could reverse that and show activity. Secondly, we were able to activate the immune system and enhance anti-tumor activity in first-line patients, and that's important because the immune system is much more functional in these early settings, first-line even in the neoadjuvant, earlier stage setting, too. And thirdly, activating and enhancing anti-tumor activity in these cold tumors, such as fourth-line colorectal. For example, in colorectal, we showed activity. We showed tumor shrinkage in multiple patients as well, and that's a very, very late line patient population. So that was the, we did learn all of these things in terms of the overall program in head and neck. Also, we showed enrichment in terms of activity for specific subsets, also based on the immune context of these tumors as well. And then in terms of the cadence, yes, we'll continue to follow up what we call the non-prioritized tumor types, and we'll continue to report data as they evolve. We made it clear, actually, in our disclosure a couple of weeks ago that this was interim data, and of course, because that durability is so important, that's what we will be following up on.
Theresa LaVallee, Other
And maybe to add on that, I mean, we selected esophageal cancer because it exceeds benchmarks. So it's a streamlined development. We showed activity across the board. I mean, so Saturday, I was in Phoenix at the SITC conference, and BMS showed their data with NICE activity in non-small cell lung cancer. They've also seen activity in colorectal speaking to the gentleman at the poster, and he said that their plans were to go on top of long-serve BEV, which our data would support that as well. But clearly, then, it's get the combination data, show the activity, and then do the development. So what Denny said very clearly on our call yesterday and what we've talked about is wanting to engage partners. And this data set, having activity, it's hard to talk to someone about a colorectal development when you haven't shown you have activity there. So we've done that, and now we can have conversations with folks about how to develop in colorectal cancer across the board, head and neck, gastric, with other agents, Whether it be standard of care or ADCs is a modality that's really showing great promise in multiple disease settings, that combination safety data with chemotherapy sets us up. And then the remodeling of the tumor microenvironment with the T-cell engagers really has a lot of promise, and we're just about to start our study with PASRIDAMIG, a KLK2 TCE in prostate cancer. So I think the totality of the data that we saw and how we'll follow up on it would be engaging partners, looking at other combinations to keep advancing tagmoketodes.
Paul Jang, Analyst — Guggenheim
Teresa, just one follow-up question. With respect to J&J's and the TCE and remodeling microenvironment, after that safety study reads out and reads out satisfactorily, how do we think about other TCEs and different areas to go?
Theresa LaVallee, Other
Yeah, so, I mean, the metric for this study seeing success, in my mind, is safety. Because once we've set up that it's safe to combine Tegmo-Ketug with a T-cell engager, the biology that we've shown across solid tumors with removing the Tregs, increasing the CD8s, really the bane of T-cell engagers and solid tumors, is that they have to bind the tumor and the T-cell at the same time to activate it. If there's a low density of T-cells, you know, just you're not going to hit your neighbor. So I think that safety alone will be exciting. Of course, we are encouraged by the data that J&J showed on Saturday at CITC where their combination with the PSMA CD28 with PASRIDAMIG improved activity and had safety. So we know that you can increase what they're seeing there, and looking forward to TAGMO-Ketug showing efficacy as well, but safety alone would be enough to really open up the field.
Paul Jang, Analyst — Guggenheim
Okay. I'm worried that we're running a long time. I did want to spend one minute on Lactorsi and just, you know, essentially, what's the major near-term focus on driving commercial sales and increased penetration into the nasopharyngeal segment?
Denny Lanphier, CEO
Great. So, in MPC, I think the primary thing there is that we have really outstanding six-year survival data, 64.7 months versus, you know, 33.5 months for chemo alone. And during 2026, we've been able to really advance the awareness of the physicians and the health care providers there. But it's very frustrating, however, that we're still at 20%, 22% market share. There's about 30% market share with chemo alone, which is a real detriment to the patients. And then, you know, 40% market share in off-label I.O. Now, we're making good progress against these, but I think that we have to go faster, And we have to advance, for the patients, we have to advance here a little bit quicker. With respect to the chemo-only segment, what we're doing there is we've engaged with a number of community oncology groups. We're actually, you know, reviewing their records. We're identifying the chemo-only patients because we can then, per our label, add Lactorsi to that. So that's one of our key strategies. And the messaging is highly focused on the six-year survival, of course. Secondarily, though, with respect to the off-label I.O., we've put in step edits in conjunction with the payers. And what that does really is sort of, you know, alert the doctors that, look, you know, there is an approved therapy with outstanding data and make them step through it. That's also proving very effective with the payers that we have put the step edit in. We're about, oh, maybe 60% market share instead of the low 20s. And so in 2027, then we're going to extend that strategy also. We need to drive that business a little faster over the next four or five quarters, I would say. And particularly, I want to get it up to the point to where those sales are covering our core burn, you know, which is ex the clinical studies and the development budget. Prior to our focusing, that required about $30 million to $35 million a quarter. But with our reduced footprint in our focus, now we're down to $25 million, $30 million a quarter. We should be able to get to that break-even point. So I've got the team really highly focused on the commercial story. And I actually met with them all and did a group call yesterday and a Zoom. So I look forward to moving the ball there over the next four quarters.
Paul Jang, Analyst — Guggenheim
Okay, fantastic. So I think with that, we're up on our time. But it was really great to speak with you all today at such an exciting time for the company. And I really appreciate you coming.
Denny Lanphier, CEO
Thank you, Paul. Thank you. Thank you.